• ACM Research, Inc. recently filed a US$135.27 million shelf registration for 2,624,473 shares of Class A common stock related to its employee stock ownership plan, following fourth-quarter 2025 results that showed sales of US$244.43 million and net income of US$8.05 million.
• Despite higher quarterly and full-year sales in 2025 compared with 2024, ACM Research’s net income and earnings per share were lower, highlighting the trade-off between growth investment and current profitability.
• Against this backdrop, we’ll now examine how the new shelf registration and potential share issuance may influence ACM Research’s investment narrative.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

ACM Research Investment Narrative Recap

To own ACM Research, you need to believe its wafer cleaning and advanced packaging tools can convert AI and chip investment into durable demand, while the company manages concentrated exposure to China and export controls. The new US$135.27 million ESOP shelf registration looks modest next to ACM’s US$901.31 million in 2025 sales, so any near term impact on the key catalyst of tool adoption and the main risk of China dependence appears limited for now.

The most relevant update here is the 2025 earnings release, which showed higher annual sales but lower net income and diluted EPS of US$1.37. That tension between growth spending and profitability frames how investors might view incremental share issuance for employee plans: it supports talent retention around new products, yet arrives as margins are under pressure and export control and China concentration risks remain front of mind.

Yet this potential dilution risk is something investors should be aware of, because...

ACM Research's narrative projects $1.4 billion revenue and $189.6 million earnings by 2028. This requires 19.1% yearly revenue growth and a $77.5 million earnings increase from $112.1 million today.

Uncover how ACM Research's forecasts yield a $70.50 fair value, a 47% upside to its current price.

Exploring Other Perspectives

The most optimistic analysts were assuming revenue could reach about US$1.5 billion and earnings US$193.4 million, so compared with the ESOP related share issuance and the risk that ACMS Shanghai’s growing role may dilute parent level earnings, their view highlights how much expectations can differ and why you should weigh several perspectives before deciding what this new filing might mean for your own thesis.

Explore 3 other fair value estimates on ACM Research - why the stock might be worth as much as 47% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your ACM Research research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free ACM Research research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ACM Research's overall financial health at a glance.

Ready For A Different Approach?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Invest in the nuclear renaissance through our list of 86 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.